Abstract

Mouse studies have shown that the immune system can reject tumours, and the identification of tumour antigens that can be recognized by human T cells has facilitated the development of immunotherapy protocols. Vaccines against cancer aim to induce tumour-specific effector T cells that can reduce the tumour mass, as well as tumour-specific memory T cells that can control tumour relapse. Owing to their capacity to regulate T-cell immunity, dendritic cells are increasingly used as adjuvants for vaccination, and the immunogenicity of antigens delivered by dendritic cells has now been shown in patients with cancer. A better understanding of how dendritic cells regulate immune responses will allow us to better exploit these cells to induce effective antitumour immunity.

Author affiliations

1. Baylor Institute for Immunology Research, 3434 Live Oak, Dallas, Texas 75204, USA.

Correspondence to: Jacques Banchereau¹ Email: jacquesb@baylorhealth.edu

Correspondence to: A. Karolina Palucka¹ Email: karolinp@baylorhealth.edu

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.